Executive Summary
CMS widened the Medicare aperture for Edwards' TAVR platform this week, arriving alongside a Dutch registry transportability analysis of the DEDICATE trial in JTCVS testing whether low/intermediate-risk TAVR outcomes hold outside the RCT population — a pairing that tightens the reimbursement case while the durability case still needs adjudication. A single-center propensity-matched comparison of newer-generation balloon-expandable versus self-expanding valves found SEVs delivered lower gradients and less bioprosthetic valve dysfunction (HR 0.64), with no mortality signal. SGLT2 inhibitor use in diabetic M-TEER patients was associated with a 32% reduction in 1-year mortality in a TriNetX cohort, adding a medical-therapy lever to the transcatheter mitral pathway.
- Newer-generation SEVs beat BEVs on hemodynamics and BVD in a matched 354-pair cohort, but mortality was identical (J Cardiovasc Med).
- Evolut 34mm large-annulus TAVI matched regular sizes on 5-year mortality, stroke, and SVD in 141 matched pairs (Cath Cardiovasc Interv).
- SGLT2i use in T2DM patients undergoing M-TEER cut 1-year mortality (HR 0.68) and MAKE (HR 0.47) (J Cardiovasc Med).
- Elevated preprocedural plasma volume status independently predicted 5-year mortality after M-TEER (63% vs 26%) (Clin Res Cardiol).
- CMS expanded Medicare coverage for Edwards TAVR, an incremental tailwind ahead of Oct 29 earnings (OCBJ).
What to watch: Edwards reports Q3 earnings October 29 — the first quarter to reflect the CMS coverage expansion and the first read on whether asymptomatic AS referrals are moving post-EARLY TAVR.
Aortic Valve (TAVR/TAVI)
Two device-comparison signals sharpen the platform debate. In a single-center propensity-matched analysis (354 pairs, non-randomized, 2018–2023), newer-generation self-expanding valves produced lower discharge gradients and a 36% reduction in bioprosthetic valve dysfunction (HR 0.64, p=0.013), driven by less severe PPM and less moderate SVD — with identical mortality. ACC/AHA 2020 and ESC 2025 both list small or challenging annular anatomy as a factor favoring SAVR, where modern surgical bioprostheses with annular enlargement still produce the lowest gradients and PPM rates in experienced hands. That hemodynamic story is echoed in a smaller SAPIEN vs Evolut retrospective published in Cureus, though that comparison is single-center and non-randomized.
Large-annulus anatomy — historically a TAVI weak spot — held up in a 141-pair matched comparison of Evolut 34mm vs 23–29mm valves, with equivalent 5-year mortality (HR 1.06), stroke, and SVD stage 3 (0% vs 1.6%). Valve-in-valve with the Navitor platform delivered mean gradients of 16.8 mmHg and 86.7% VARC-3 early safety in 30 patients — acceptable results from a sample too small to draw conclusions about durability or rare complications. ESC 2025 and ACC/AHA 2020 both flag future valve-in-valve feasibility as a critical lifetime-management consideration at the index procedure. Two mechanistic reads: annular eccentricity and sinus height predicted 1-year LV reverse remodeling (n=115, hypothesis-generating), and loss of septal Q waves flagged conduction vulnerability in patients without baseline block (N=87). A case report of acute common carotid occlusion after transcarotid TAVI is a reminder that alternative access carries real procedural cost.
Mitral Valve (MitraClip, PASCAL, TMVR)
In 311 prospectively enrolled M-TEER patients, elevated preprocedural estimated plasma volume status independently predicted mortality (HR 2.38), and the combination of elevated ePVS plus NT-proBNP identified a group with 14-fold higher hazard — a cheap risk-stratifier that outperforms clinical gestalt for subclinical congestion. Separately, a TriNetX propensity-matched cohort of 650 diabetic M-TEER patients found SGLT2i use associated with 32% lower 1-year mortality and 53% reduction in major adverse kidney events — retrospective and confounded by prescriber selection, but directionally consistent with the broader HF SGLT2i literature.
Neither finding changes the procedural hierarchy. ESC 2025 elevated TEER for ventricular secondary MR to Class I, LOE A, based on COAPT, RESHAPE-HF2, and meta-analysis; ACC/AHA 2020 holds at IIa. For primary MR, both guidelines favor surgical repair when a durable result is achievable — and ESC 2025 expanded early-surgery indications in asymptomatic patients meeting risk criteria (AF, pulmonary hypertension, LA dilation, TR) to Class I. Both findings refine who benefits most from the transcatheter option within that hierarchy, not whether the hierarchy holds.
Surgical vs. Transcatheter Comparisons
[NOTABLE] JTCVS published a DEDICATE transportability analysis using the Netherlands Heart Registration to test whether the trial's low/intermediate-risk TAVR-vs-SAVR results hold in a real-world Dutch population. DEDICATE was the investigator-initiated trial that reported TAVR death+stroke of 5.4% vs 10.0% at 1 year — a result that contributed to ESC 2025 lowering its TAVI-preferred age threshold to 70. Registry-based external validation is precisely where RCT enthusiasm tends to soften: real-world populations carry more comorbidity, less protocol discipline, and operator-volume heterogeneity that trial sites suppress. If the Dutch cohort shows an attenuated TAVR advantage — as has occurred with prior real-world validations — the ESC's age-70 pivot looks aggressive. ACC/AHA 2020 holds SAVR preference below age 65 and TAVI preference above 80, a more conservative posture that the available durability data through 5–10 years still supports. The full paper is the read of the week.
Device & Technology
A 63-patient single-center study in the Journal of Cardiovascular Computed Tomography found photon-counting CT detected post-TAVR valve dysfunction with AUC 0.94, sensitivity 88.9%, specificity 88.6% against TTE reference. Clinically interesting: PCCT delivers anatomical and hemodynamic data in one acquisition. At current PCCT availability, this is an academic-center offering, not a community workflow.
Regulatory & Policy
CMS expanded Medicare coverage for Edwards' TAVR platform. Details on scope are thin in the initial reporting, but any expansion of the covered population is directly accretive to procedure volumes at a time when EARLY TAVR is already pulling asymptomatic severe AS into the treatment funnel.
Industry & Market
SNS Insider published a prosthetic heart valve market outlook for 2026–2035. Third-party market reports of this genre are marketing collateral more than sell-side analysis; treat sizing figures directionally.
Financial Analysis
Two catalysts stack for Edwards this week: CMS coverage expansion and the DEDICATE transportability paper. The coverage decision is a straightforward volume tailwind. DEDICATE is more nuanced: if the Dutch registry validates the trial's TAVR benefit, it reinforces the ESC age-70 pivot and supports continued share expansion into younger cohorts — bullish for both Edwards and Medtronic. If it doesn't, the low-risk indication-creep narrative gets a headwind. Edwards trades at 26.5x forward earnings with a $101 consensus target (14% upside) — priced for continued procedure growth, not for durability disappointment. Boston Scientific's 36% six-month drawdown reflects the Farapulse/EP story rather than structural heart, but the multiple compression makes BSX's TriClip and other structural assets cheaper on a sum-of-parts basis.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close $89.54, +1.35% on the day; six-month performance +9.16%.
- Market cap $51.6B; trailing P/E 53.3; forward P/E 26.5; beta 0.85.
- 52-week range $72.30–$96.29; consensus target $100.96 (buy, 26 analysts).
- Q3 earnings October 29 — EPS est $0.74, revenue est $1.68B.
- CMS coverage expansion is the immediate catalyst; the DEDICATE transportability read matters more for the medium-term valuation.
Medtronic (MDT)
- Close $91.89, +0.16%; six-month +7.24%.
- Market cap $117.5B; forward P/E 14.3; beta 0.57.
- Consensus target $104.83 (buy, 24 analysts); earnings November 17.
- Evolut 34mm large-annulus data reinforces the SEV platform story ahead of the DEDICATE JTCVS readout.
Abbott (ABT)
- Close $103.32, +0.33%; six-month essentially flat at -0.13%.
- Market cap $180B; forward P/E 17.0; target $120.26 (buy).
- Q3 earnings October 14. MitraClip continues to benefit from the ESC 2025 Class I upgrade for ventricular SMR.
Boston Scientific (BSX)
- Close $44.40, +1.56%; six-month -36.15% — the worst performer in the group.
- Market cap $64.4B; forward P/E 13.0; target $61.07 (buy, 29 analysts).
- Earnings October 28. Structural heart (Acurate neo2, PolarX) remains a smaller share of the story than EP; the drawdown creates a cheaper structural entry.
Anteris Technologies (AVR.AX)
- Close A$11.27, -1.74%; six-month +40.88% — the outperformer.
- Market cap A$1.1B; forward P/E negative (pre-commercial); single analyst target A$13.
- DurAVR THV single-piece bovine pericardial platform continues to generate early enthusiasm; no near-term earnings catalyst.
Market outlook: The structural heart names are a two-engine trade — TAVR volume expansion (Edwards, Medtronic) and mitral/tricuspid transcatheter growth (Abbott, Edwards, BSX). CMS coverage expansion, the ESC 2025 Class I upgrade for ventricular SMR TEER, and the emerging tricuspid category are all constructive. The offset is durability: as more low-risk and asymptomatic patients receive transcatheter valves, the 10-year SVD question moves from academic to actuarial.
Clinical Trial Updates
Aortic:
- No new aortic valve trials with status changes reported today. [LANDMARK] EARLY TAVR, DEDICATE, PARTNER 3, and Evolut Low Risk continue to define the low-risk and asymptomatic space; DEDICATE transportability data published today in JTCVS.
Mitral / Tricuspid:
- No new mitral or tricuspid trials with status changes today. [LANDMARK] COAPT, RESHAPE-HF2, TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II remain the reference set for the ESC 2025 Class I (TEER for ventricular SMR) and Class IIa (transcatheter TR) upgrades.
The only ClinicalTrials.gov entry updated today (NCT07834723, NIV-NAVA in infant bronchiolitis) is unrelated to structural heart.
What next: The full DEDICATE transportability paper in JTCVS is the read of the week — it will either reinforce or complicate the ESC 2025 case for shifting the TAVI age threshold to 70, and the answer flows directly into what SAVR volumes look like over the next five years.